Unlawful Mixed Pricing in Germany Early Benefit Assessment

On 1 March 2017, the Landessozialgericht (LSG) of Berlin-Brandenburg passed an urgent decision on medicinal products which are subject to the early evaluation of the use of medicinal products, declaring that the mixed price formation for medicinal products is unlawful if no sub-groups have been identified by the G-BA.

This decision is thought to affect around 20% of all medicines evaluated through AMNOG.

Read the full story here.

Tagged with

Published 13. April 2017 in News Germany